Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trontinemab versus placebo in early symptomatic Alzheimer's disease
2024-518008-33-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Trontinemab with Placebo (2 arms). Primary endpoint: Change from baseline to Week 72 in Clinical Dementia Rating, Sum of Boxes. Planned start Nov 2025; status: authorised.
02
Drugs
trontinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-518008-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518008-33-00.